Innovation Across Industries - Health, Technology & More
We are pleased to spotlight recent achievements from a select few of our portfolio of pioneering Featured Companies. From clinical progress to product launches, global expansion, and more - it’s an energizing time of innovation across health, tech, shipping and sustainability sectors.
Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)
Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease announced the Company has reached alignment with the U.S. Food and Drug Administration (FDA) on the path forward for Oxylanthanum Carbonate (OLC) and on the overall package requirements to file a New Drug Application.
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs.
Jaguar Health, Inc. (Nasdaq: JAGX), under its Jaguar Animal Health tradename for the veterinary market, announced that the U.S. Food and Drug Administration (FDA) has approved the renewal of Canalevia-CA1 (crofelemer delayed-release tablets). Canalevia-CA1, the company's conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is available from multiple leading veterinary distributors in the U.S., including Chewy.
Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa
Kiora Pharmaceuticals, Inc. (Nasdaq: KPRX) announced its third quarter 2023 financial results and is providing an update on its plans to advance clinical development of KIO-301 for other inherited retinal diseases.
TOP Ships Inc. Announces Extension of Time Charter Employment for Two VLCC Tankers
TOP Ships (Nasdaq: TOPS) announced that it has agreed to extend the time charter employment contracts of its two VLCC vessels, M/T Julius Caesar and M/T Legio X Equestris, at an increased rate. Specifically, the firm period will be extended for approximately 3 years at a daily rate of $41,500 per vessel with two additional years at the charterer's option.
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
AIM ImmunoTech Inc. (NYSE American: AIM) announced the last subject has completed treatment in the Company's Phase 2 study evaluating Ampligen® as a potential therapeutic for people with the post-COVID condition of fatigue ("AMP-518").
GRI Bio Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis
GRI Bio (Nasdaq: GRI) announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug ("IND") application for GRI-0621 for the treatment of IPF. The Company plans to evaluate GRI-0621 in a randomized, double-blind, multi-center Phase 2a biomarker study, on track to commence before year end.
As 2023 draws to a close, our Featured Companies reinforce our optimism for the new year ahead. Though brief, we hope these updates provide a glimpse into the progress being made to deliver better patient outcomes, enable financial access and inclusion, develop cleaner technologies for our planet, and create shareholder value.
Please try to join us at one of the above-mentioned Featured Conferences so we can meet in person. If you want to participate as an investor, presenter, or sponsor, contact me directly, and I will do what I can to facilitate.
As always, I thank you for your continued interest and partnership, and I welcome any discussions where we can collaborate further with you or your firm. Please reach out to me by email, phone, or LinkedIn.
David Shapiro Chief Executive Officer B2i Digital, Inc. 212-579-4844 (office) 917-806-4171 (cell)
Feel free to Follow B2i Digital on LinkedIn. Then send me a message. I will be happy to reciprocate and follow your page or profile.
B2i Digital, Inc. provides digital marketing support to the above-mentioned Featured Companies, the Featured Companies hosted on b2idigital.com, and the Featured Conference companies hosted on b2idigital.com. B2i Digital has not independently verified the accuracy of the information contained herein or on b2idigital.com. The content was provided by the Companies or from publicly available sources. B2i Digital, Inc. makes no warranties regarding the accuracy of any information provided. No content contained herein or on b2idigital.com shall be considered an offer to solicit the sale of any security or be considered as an opinion as to its investment suitability. Full disclaimer: https://b2idigital.com/disclaimer.
B2i Digital, Inc., 401 2nd Avenue, New York, New York 10010
